Skip to content

The effect of Cold Plasma Activated Solution on the face to treat Skin aging

Permeation of Plasma-Activated Solution in the Treatment of Skin aging

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-10ns38c6
Enrollment
Unknown
Registered
2025-01-28
Start date
2025-01-06
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Aging

Interventions

This is a randomized, single-blind, controlled clinical study. Sample of 100 participants. Women aged 40 to 60 years, skin phototype II, III and IV and facial photoaging grade I to IV according to the
Control group: 50 women will receive microneedling to perform the drug delivery technique and 0.9% SF not activated by cold plasma will be used. The study volunteers will receive application of the mi

Sponsors

Universidade Brasil
Lead Sponsor
Universidade Brasil
Collaborator

Eligibility

Sex/Gender
Female
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Female patient; age between 40 and 60 years; phototype II, III, and IV according to the Fitzpatrick scale; presence of signs of facial photoaging grade I to IV according to the Glogau scale; Signed informed consent

Exclusion criteria

Exclusion criteria: Active infections such as herpes at the site where the procedure is performed; with tendencies to keloid healing and hypertrophic scarring; Pregnant; Rosettes; skin cancer; uncontrolled diabetes; use of some type of cosmetic in the facial region in the last six months, whose indication is for the minimization of facial aging, such as: Antioxidant, Kojic Acid, Salicylic Acid and Retinol; performance of rhytidoplasty and/or blepharoplasty, and ablative chemical or physical peeling in the last 12 months; and, use of botulinum toxin or fillers with collagen implants in the last six months; patients using photosensitizing drugs; patient with impossibility of photoprotection during the entire treatment period; patients with active skin diseases in the facial region; presence of implanted electronic or metallic devices; patient with suspected or diagnosed photosensitive epilepsy; Refusal to sign the free consent form

Design outcomes

Primary

MeasureTime frame
An improvement in the aged and dehydrated appearance of the skin is expected.

Secondary

MeasureTime frame
An improvement in the patient's self-esteem is expected; It is still expected to obtain the quality of the skin; improve skin blemishes and/or scars.

Countries

Brazil

Contacts

Public ContactAna Keila Ferreira dos Santos

Universidade Brasil

keilla_anna@hotmail.com+55-11-48589224

Outcome results

None listed

Source: REBEC (via WHO ICTRP)